Which type of antidiabetic drug does Sitagliptin belong to?

Sitagliptin is a dipeptidyl peptidase -4 (DPP-4) inhibitor among antidiabetic drugs. It is a type of oral drug used to treat type 2 diabetes. Its mechanism of action mainly involves the regulation of glucagon (GLP-1).

DPP-4inhibitors are a class of drugs that work by inhibiting the activity of DPP-4enzyme. DPP-4 is an enzyme present on the surface of human pancreatic islet cells. Its main function is to decompose GLP-1. GLP-1 is a hormone secreted by the epithelial cells of the small intestine. It promotes the release of insulin after food intake, thereby lowering blood sugar levels. However, GLP-1 has a relatively short life cycle because it is quickly broken down by DPP-4enzyme.

The function of sitagliptin is to prevent the premature degradation of GLP-1 by inhibiting the activity of DPP-4 enzyme, thereby prolonging the life cycle of GLP-1. In this way, GLP-1 can more fully exert its hypoglycemic effect, increase insulin secretion, reduce the liver's production of glucose, slow down the absorption of food in the gastrointestinal tract, and ultimately help lower blood sugar levels.

Unlike some other antidiabetic drugs,One of the advantages of DPP-4inhibitors is their relatively mild antidiabetic effect, reducing the risk of hypoglycemia. It is usually used as monotherapy or in combination with other oral hypoglycemic drugs, insulin, etc. to develop an individualized diabetes treatment plan.

In general, sitagliptin, as a DPP-4 inhibitor, belongs to a class of oral anti-diabetic drugs that achieve hypoglycemic effects by regulating the GLP-1 metabolic pathway. Patients should follow their doctor's advice when using sitagliptin and conduct regular monitoring and follow-up to ensure the effectiveness and safety of the drug.